Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study.

Ipragliflozin add-on therapy can be a viable option for better glycemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulfonylurea. This article is protected by copyright. All rights reserved.